MYGN Q2 2023 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q2 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$184M+2.3% YoY

Gross Profit

$126M68.5% margin

Operating Income

-$114M-62.0% margin

Net Income

-$116M-63.3% margin

EPS (Diluted)

$-1.42

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

-$900,000

Free Cash Flow

-$20M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$452M

Stockholders' Equity

$735M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$184M	$179M	+2.3%
Gross Profit	$126M	$130M	-3.0%
Operating Income	-$114M	-$18M	-538.8%
Net Income	-$116M	-$14M	-723.4%

Geographic Segments

UNITED STATES

$27M76%

Non-US

$9M24%